SurVaxM is the first drug product to be produced in UI Pharmaceuticals new facilityUI Pharmaceuticals is looking forward to supporting…
Study Marks Milestone in Precision Psychiatry for Stress-Axis-Related DepressionMUNICH, Jan. 10, 2025 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC”), a…
- Signals Start of New Commercialization Phase for LineaRx Subsidiary -- Company Negotiating GMP Supply Agreement -- Company Reaffirms Strategic…
This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform,…
In Q1 2025, the Company will discuss the plans for NDA submission under a potential accelerated approval path for bitopertin…
Highly experienced management team with a successful track record in advancing compounds from target identification to commercialization Top-tier global investors…
First Quarter Fiscal 2025 Revenue Includes a One-Time Upfront Payment of $3.0 Million in Collaboration Revenue from Zimmer Biomet and…
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage…
TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- InflammX Therapeutics Inc., a clinical-stage biotechnology company focused on developing innovative therapies…
Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS)…